Recurrent, platinum-resistant, CPS >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients research hub

Prospective, non randomized, Phase II study on MK-3475 in recurrent, platinum-resistant, CPS ≥1 positive ovarian, Fallopian tube and primary peritoneal cancer patients

This study tests whether an immunotherapy drug called Keytruda can help women with ovarian, fallopian tube, or peritoneal cancer. It looks at women whose cancer has returned after standard platinum chemotherapy and whose tumours have a specific protein marker, measuring if the treatment helps them live longer.